Latanoprost versus combined timolol and dorzolamide

Survey of Ophthalmology

Volumn 47, Issue 4 SUPPL. 1, 2002, Pages

  Bron, Alain M ^a   Emmerich, Karl Heinz ^b  

^a HÔPITAL DU BOCAGE   (France)

^b Eye Clinic   (Germany)

Author keywords

Additivity; Dorzolamide; Latanoprost; Open angle glaucoma; Timolol

Indexed keywords

DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; PROSTAGLANDIN DERIVATIVE; TIMOLOL;

AQUEOUS HUMOR FLOW; BLEPHARITIS; CIRCADIAN RHYTHM; CLINICAL PRACTICE; CLINICAL TRIAL; CONJUNCTIVA DISEASE; CONJUNCTIVAL HYPEREMIA; CORNEA DISEASE; DRUG ACTIVITY; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRY EYE; EPIPHORA; EYE COLOR; EYE IRRITATION; EYE PAIN; FLU LIKE SYNDROME; HEADACHE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; META ANALYSIS; METABOLIC DISORDER; OPEN ANGLE GLAUCOMA; PATIENT COMPLIANCE; PHOTOPHOBIA; PRESCRIPTION; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; SIDE EFFECT; SKIN DISEASE; UVEITIS; VISUAL IMPAIRMENT;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CARBONIC ANHYDRASE INHIBITORS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; OCULAR HYPERTENSION; PROSTAGLANDINS F, SYNTHETIC; SULFONAMIDES; THIOPHENES; TIMOLOL;

EID: 0036669557     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6257(02)00290-4     Document Type: Review

References (32)

1. Alm A., Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 102:1995;1743-1745.
2. Alm A., Widengard I., Kjellgren D.et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol. 79:1995;12-16.
3. Baudouin C., Garcher C., Haouat N.et al. Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology. 101:1994;454-456.
4. Boger W.P. 3rd, Puliafito C.A., Steinert R.F., Langston D.P. Long-term experience with timolol ophthalmic solution in patients with open-angle glaucoma. Ophthalmology. 85:1978;259-267.
5. Boles Carenini B., Brogliatti B., Spinelli D. Latanoprost in monotherapy compared with Timolol and Dorzolamide in association as hypotensive agents in primary open-angle glaucoma and ocular hypertension. An open, randomized, multicentric, Italian study. Acta Ophthalmol Scand. 77(Suppl):1999;53. -.
6. Boyle J.E., Ghosh K., Gieser D.K., Adamsons I.A. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group. Ophthalmology. 105:1998;1945-1951.
7. Broadway D., Hitchings R., Grierson I. Topical antiglaucomatous therapy: Adverse effects on the conjunctiva and implications for filtration surgery J Glaucoma. 4:1995;136-148.
8. Camras C.B. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: A six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group Ophthalmology. 103:1996;138-147.
9. Emmerich K.H. Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension. A 3-month randomised study. Graefes Arch Clin Exp Ophthalmol. 238:2000;19-23.
10. Fechtner R., Clineschmidt C., Getson A., Adamsons I. A three month, parallel, randomized, observer-masked, multicenter study comparing Cosopt to Xalatan in patients with elevated IOP. Invest Ophthalmol Vis Sci. 40(Suppl):1999;S665. [abstract].
11. Fiscella R.G., Geller J.L., Gryz L.L.et al. Cost considerations of medical therapy for glaucoma. Am J Ophthalmol. 128:1999;426-433.
12. Garcia Sanchez J. Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension-a three-month randomised study. Spanish Latanoprost Study Group. Eur J Ophthalmol. 10:2000;198-204.
13. Greenberg R.N. Overview of patient compliance with medication dosing: A literature review Clin Ther. 6:1984;592-599.
14. Italian Multicentric Open Randomized Study under the aegis of AISG: Final results and official report. Hypotensive efficacy in primary open-angle glaucoma and ocular hypertension: Latanoprost in monotherapy vs timolol and dorzolamide in association. Acta Ophthalmol Scand 78 (Suppl):49-50, 2000
15. Kobelt G., Jonsson L., Gerdtham U., Krieglstein G.K. Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany. Graefes Arch Clin Exp Ophthalmol. 236:1998;811-821.
16. Lee M.D., Fechtner F.R., Fiscella R.G.et al. Emerging perspectives on glaucoma: Highlights of a roundtable discussion Am J Ophthalmol. 130:2000;S1-11.
17. Lee P.Y., Shao H., Camras C.B., Podos S.M. Additivity of prostaglandin F2 alpha-1-isopropyl ester to timolol in glaucoma patients. Ophthalmology. 98:1991;1079-1082.
18. Liesegang T.J. Conjunctival changes associated with glaucoma therapy: Implications for the external disease consultant and the treatment of glaucoma Cornea. 17:1998;574-583.
19. Mishima H.K., Masuda K., Kitazawa Y.et al. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Arch Ophthalmol. 114:1996;929-932.
20. Nagasubramanian S., Sheth G.P., Hitchings R.A., Stjernschantz J. Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens. Ophthalmology. 100:1993;1305-1311.
21. Odberg T. Dorzolamide-timolol combination versus concomitant administration of its components. Ophthalmology. 106:1999;1044-1045.
22. Orzalesi N., Rossetti L., Invernizzi T.et al. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 41:2000;2566-2573.
23. Polo V., Larrosa J.M., Gomez M.L.et al. Latanoprost versus combined therapy with timolol plus dorzolamide: IOP-lowering effect in open-angle glaucoma Acta Ophthalmol Scand. 79:2001;6-9.
24. Rulo A.H., Greve E.L., Hoyng P.F. Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure. Br J Ophthalmol. 78:1994;899-902.
25. Schlecht L.P., Brubaker R.F. The effects of withdrawal of timolol in chronically treated glaucoma patients. Ophthalmology. 95:1988;1212-1216.
26. Stewart W.C., Hudgins A.C., Pruitt C.A., Sine C. Daily cost of newer glaucoma agents. J Ocul Pharmacol Ther. 15:1999;379-388.
27. Strahlman E., Tipping R., Vogel R. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group. Arch Ophthalmol. 113:1995;1009-1016.
28. Susanna R. Jr., Nicolela M.T., Oga E., Sine C. Additive effect of latanoprost to the combination of timolol and dorzolamide. J Glaucoma. 9:2000;183-186.
29. Topper J.E., Brubaker R.F., Topper J.E., Brubaker R.F. Effects of timolol, epinephrine, and acetazolamide on aqueous flow during sleep. Invest Ophthalmol Vis Sci. 26:1985;1315-1319.
30. Villumsen J., Alm A. The effect of adding prostaglandin F2 alpha-isopropylester to timolol in patients with open angle glaucoma. Arch Ophthalmol. 108:1990;1102-1105.
31. Vold S.D., Wiggins D.A., Jackimiec J. Cost analysis of glaucoma medications. J Glaucoma. 9:2000;150-153.
32. Watson P., Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology. 103:1996;126-137.